NR3C2 and diabetic kidney disease: Finerenone, a novel selective mineralocorticoid receptor antagonist (MRA), has manifested both cardiovascular and kidney protection confirmed by two phase III trials, Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease (FIDELIO-DKD) (145) and Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) (146) together with FIDELITY pooled analysis (147).